Data as of Mar 14
| +0.13 / +2.15%|
The 1 analysts offering 12-month price forecasts for Rosetta Genomics Ltd have a median target of 3.50, with a high estimate of 3.50 and a low estimate of 3.50. The median estimate represents a -43.46% decrease from the last price of 6.19.
The current consensus among 1 polled investment analysts is to Hold stock in Rosetta Genomics Ltd. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.